The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,741.00
Bid: 1,740.50
Ask: 1,741.00
Change: 1.00 (0.06%)
Spread: 0.50 (0.029%)
Open: 1,730.00
High: 1,745.00
Low: 1,729.00
Prev. Close: 1,740.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Gains Held Back By Miners

Thu, 21st Aug 2014 16:29

LONDON (Alliance News) - UK stocks made gains on Thursday as equity markets across Europe and the US also made strong gains, but the FTSE 100 was held back by mining stocks which were hit by concerns about growth in China.

In the US, the DJIA moved back above 17,000 points, while the S&P 500 hit a new record intraday high, after strong economic data was released. In particular, the US manufacturing PMI came in at 58, up from 55.8 in June and well above economists' expectations for 55.7. It was the highest reading since April 2010.

After the European market close, the DJIA was up 0.4%, the S&P 500 up 0.3%, although the Nasdaq Composite was flat.

European equity markets posted even stronger gains, with the CAC 40 ending up 1.2% and the DAX up 0.9%, despite mixed PMI data.

The eurozone composite PMI slipped to 52.8 in August, from 53.8 in July, missing expectations of 53.4, and the services PMI dropped to 53.5, from 54.2 in July. In Germany, the region's biggest economy, output slowed fractionally. The manufacturing sector PMI came in at 52.0, down from 52.4, but beating expectations of 51.8, while the service sector print was 56.4, down from 56.7, also beating expectations of 55.5.

In the context of the gains in Europe, the London market underperformed as its high number of mining sector constituents weighed. The FTSE 100 ended up 0.3% at 6,777.66, while the FTSE 250 finished up 0.6% at 15,838.57 and the AIM All Share index ended down 0.1% at 763.96.

Mining stocks fell after the Chinese manufacturing PMI slipped to a three month low at 50.3, down from 51.7 in July and missing the market consensus of 51.5. The FTSE 350 mining sector index ended the day down 0.6% with Fresnillo down 3.6%, Randgold Resources down 1.9% and Anglo American down 1.3%.

In the FTSE 250, miner Kazakhmys was the biggest faller, ending down 5.6%. Its pretax loss narrowed in the first-half due to lower write-offs and impairment charges and as its cost cutting programme and efficiency improvements offset lower metals prices and boosted margins. However, revenue fell as it reduced output at several higher cost, lower grade operations as part of its restructuring programme.

Pharmaceuticals led the gainers on the FTSE 100.

AstraZeneca, up 3%, ended the day as the blue-chip index's biggest gainer after it said it has partnered with Illumina to develop a gene-sequencing platform for companion diagnostic tests, applicable across AstraZeneca's oncology portfolio.

The company said Illumina's technology allows gene sequencing that is faster and cheaper than traditional methods, and will be used to screen a panel of several gene sequences, scanning for possible genetic variants, rather than specified mutations from a single tumour sample. This information can then be used to help predict which patients will respond to which treatments.

GlaxoSmithKline ended the day 1.2% higher after the company said late Wednesday that the US Food and Drug Administration has approved its Arnuity Ellipta treatment for asthma in patients aged 12 years and older. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio.

The pound dropped Thursday after UK retail sales grew 2.6% on the year in July, down from 3.4% annual growth in June and below economists' forecasts for 3% growth. Sales were up just 0.1% on the month in July, down from 0.2% growth in June and missing the consensus of 0.4% growth.

"There had been some hope that the weakness seen in May and June was a temporary blip for UK consumers but the weakness is persisting into July with only 0.1% growth in the month. Employment is rising but stagnating wages against a backdrop of modest inflation means confidence in future spending ability is being hampered by a short-term squeeze in the cost of living," said Jasper Lawler, an analyst at CMC Markets.

Sterling initially fell sharply in reaction to the news, but recovered throughout the day and was trading at USD1.6590 when the equity markets closed.

Friday's economic calendar is dominated by the Jackson Hole Symposium and speeches by Federal Reserve chief Janet Yellen and European Central Bank President Mario Dragi at 1500 BST and 1930 BST, respectively.

In the corporate calendar, FTSE 250-listed HellermannTyton Group will release interim results.

By Neil Thakrar; neilthakrar@alliancenews.com

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.